Researchers report in a recent study that MDMA, a psychedelic substance, can reduce the symptoms of posttraumatic stress disorder.
The research sponsor said that it will seek U.S. FDA approval in the coming months to market the drug ecstasy (also known as ecstasy) as a PTSD medication when combined with talk therapies.
“It’s the first innovation in PTSD treatment in more than two decades. And it’s significant because I think it will also open up other innovation,” said Amy Emerson, CEO of MAPS Public Benefit Corporation, the research sponsor.
Australia became the very first country this year to allow psychiatrists the prescription of MDMA and Psilocybin – the psychoactive substance in psychedelics. Multidisciplinary Association for Psychedelic Studies, a nonprofit advocacy group, has been working to increase the acceptance of these drugs in the U.S.
Click here to read more Psychedelics may be part of U.S. medicine sooner than you think
In the new study researchers measured symptoms among 104 PTSD sufferers who were randomly assigned either MDMA, or a dummy drug, during three sessions spaced one month apart. Both groups received talks…